Collectively, B2M/CIITA double-knockout enables sustained reduction in HLA expression while preserving the MSC phenotype and immunomodulatory activity, and enhances the therapeutic efficacy of iMSCs in the mouse OA model, providing a potential strategy for developing iPSC-derived MSCs with reduced HLA expression for allogeneic cell therapy.
Abstract
Highlights What are the main findings? B2M and CIITA double-knockout eliminates HLA class I and class II expression in iPSCs and iMSCs even under inflammatory conditions, while preserving MSC phenotype, proliferation capacity, and immunomodulatory function. In mice with OA, intra-articular administration of dKO-iMSCs reduced cartilage degeneration more effectively than wild-type iMSCs and tissue-derived MSCs, without evident systemic toxicity. What are the implications of the main findings? HLA-engineered iPSCs provide a scalable approach for generating iMSCs with sustained loss of HLA class I and class II surface expression while preserving their therapeutic properties. dKO-iMSCs provide a promising platform for allogeneic OA therapy by exhibiting a less pro-inflammatory and more matrix-supportive state under inflammatory stimulation. Abstract Osteoarthritis (OA) is one of the most prevalent degenerative joint diseases, and there is no approved pharmacological therapy that can reliably reverse cartilage degeneration or restore cartilage structure. Allogeneic mesenchymal stromal cells (MSCs) have shown therapeutic potential for OA, but inflammatory conditions can enhance HLA expression and increase allogeneic immune recognition risk. Here, we generated B2M and CIITA double-knockout induced pluripotent stem cells (dKO-iPSCs) using CRISPR/Cas9 and subsequently differentiated them into dKO-iMSCs. B2M/CIITA double-knockout did not affect iPSC pluripotency, karyotype, or teratoma formation. dKO-iMSCs retained characteristic MSC phenotypes, exhibited greater proliferative capacity than tissue-derived MSCs, and could be expanded to passage 18. Notably, HLA-ABC and HLA-DR expression remained undetectable in dKO-iMSCs even after IFN-γ stimulation. In co-culture assays with PHA-L-stimulated allogeneic PBMCs, dKO-iMSCs suppressed PBMC and T-cell proliferation as effectively as wild-type iMSCs, indicating preservation of their immunomodulatory activity. Intra-articular administration of dKO-iMSCs significantly reduced cartilage degeneration in the destabilization of the medial meniscus (DMM) mouse model of OA. The treatment showed greater therapeutic efficacy than wild-type iMSCs and tissue-derived MSCs and did not cause evident systemic organ toxicity. Single-cell RNA sequencing of BM-MSCs and dKO-iMSCs after in vitro IFN-γ stimulation revealed enhanced extracellular matrix-associated cell–cell communication and markedly reduced IL1B expression in dKO-iMSCs, indicating a less pro-inflammatory and more matrix-supportive cellular state under inflammatory conditions. Collectively, B2M/CIITA double-knockout enables sustained reduction in HLA expression while preserving the MSC phenotype and immunomodulatory activity, and enhances the therapeutic efficacy of iMSCs in the mouse OA model, providing a potential strategy for developing iPSC-derived MSCs with reduced HLA expression for allogeneic cell therapy.
Mesenchymal stem cell (MSC) therapy for end-stage knee osteoarthritis (KOA) shows inconsistent efficacy, and whether MSCs retain cartilage repair capacity in the inflammatory joint remains unclear. Using single-cell RNA sequencing of human Kellgren-Lawrence grade III (G III) and IV (G IV) KOA joint tissues and exogenou...
Cartilage injury and osteoarthritis-associated degeneration remain major clinical challenges because articular cartilage is avascular, aneural, and alymphatic, leaving it with limited intrinsic capacity for repair. Current clinical strategies, including microfracture, osteochondral grafting, autologous chondrocyte impl...
Xiang-Guo Che, Xian Jin, Dong-Kyo Lee et al.· Organoid· 0 citations
Osteoarthritis (OA) is a heterogeneous disorder affecting multiple joint tissues, in which structural degeneration may be accompanied by varying degrees of synovial inflammation and immune-stromal dysregulation. Mesenchymal stem/stromal cells (MSCs) have demonstrated immunomodulatory and tissue-protective properties, i...
M. Ley, Marc C. Philippon, Ramy Labib et al.· International Journal of Mol...· 0 citations
Data from emerging preclinical and clinical trials, which show significant improvements in WOMAC and VAS scores and a decrease in DAS28 with minimal adverse effects, suggest that UC-MSCs will improve pain and function and, in turn, overall quality of life.
D. Greene, Umm E. Habiba, R. Sathyanarayanan et al.· Regenerative Therapy· 0 citations
Mesenchymal stromal cells (MSCs) have emerged as one of the most extensively studied adult stem cell populations, celebrated for their self-renewal, multilineage differentiation potential, and remarkable immunomodulatory properties. Originally discovered in bone marrow, MSCs are now known to reside in diverse tissu...
Xiao-Xia Song, Dan Wu, Dong-Xue Tang et al.· Frontiers in Cell and Develo...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.